Published in Future Oncol on November 01, 2009
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res (2015) 1.48
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology (2013) 1.12
Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem (2011) 1.00
FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One (2012) 0.99
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res (2014) 0.89
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 0.88
Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells. Prostate (2012) 0.87
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev (2010) 0.84
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat Commun (2016) 0.82
Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prev Res (Phila) (2012) 0.82
Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol (2014) 0.81
Redefining hormone sensitive disease in advanced prostate cancer. Adv Urol (2012) 0.80
Androgen receptor in laryngeal carcinoma: could there be an androgen-refractory tumor? ISRN Oncol (2011) 0.80
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One (2012) 0.79
A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. Can Urol Assoc J (2014) 0.78
Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med (2013) 0.78
Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res (2016) 0.78
ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis. PLoS One (2013) 0.77
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene (2016) 0.77
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget (2016) 0.75
A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance. Mol Cell (2016) 0.75
Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Oncotarget (2016) 0.75
Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother (2016) 0.75
Ailanthone: a new potential drug for castration-resistant prostate cancer. Chin J Cancer (2017) 0.75
Proteomics analyses of prostate cancer cells reveals cellular pathways associated with androgen resistance. Proteomics (2017) 0.75
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin (1972) 3.35
Reactive stroma in prostate cancer progression. J Urol (2001) 3.21
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res (2002) 2.99
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer (1993) 2.56
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 2.37
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res (2000) 2.22
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res (2007) 2.12
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway . Prostate (2000) 2.03
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res (1997) 1.95
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res (2000) 1.86
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res (2003) 1.80
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate (1999) 1.71
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.70
Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res (1995) 1.63
What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev (1999) 1.62
Interleukin-6: structure-function relationships. Protein Sci (1997) 1.59
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 1.50
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 1.48
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol (2001) 1.46
Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol (2001) 1.41
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate (2000) 1.40
The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res (2004) 1.38
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate (2004) 1.26
Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology (2008) 1.24
NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 1.24
A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology (2007) 1.21
Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther (2005) 1.21
Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res (1990) 1.20
Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat (2004) 1.20
Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem (1989) 1.18
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate (2004) 1.14
Role of androgens in prostatic cancer. Vitam Horm (1994) 1.14
Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res (2006) 1.13
Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol (1997) 1.08
Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett (2006) 1.06
Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol (1994) 1.06
Prostate tissue androgens: history and current clinical relevance. Urology (2008) 1.02
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol (2008) 0.99
Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene (2003) 0.93
Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev (2006) 0.92
Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Res (2001) 0.90
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 2.82
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res (2003) 1.80
Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol (2005) 1.69
Stat3 activation in prostatic carcinomas. Prostate (2002) 1.61
Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res (2006) 1.58
Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol (2013) 1.53
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem (2011) 1.52
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A (2006) 1.46
Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res (2004) 1.33
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One (2012) 1.30
Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res (2010) 1.29
Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther (2005) 1.26
NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate (2008) 1.21
Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol (2002) 1.20
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate (2004) 1.15
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate (2004) 1.14
Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate (2012) 1.10
Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res (2006) 1.09
Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate (2006) 1.07
Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate (2010) 1.05
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol (2008) 1.04
Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther (2013) 1.03
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer (2010) 1.01
Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate (2008) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics (2005) 0.99
Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate (2005) 0.99
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate (2013) 0.98
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate (2002) 0.98
Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate (2014) 0.98
Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate (2011) 0.97
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer (2011) 0.96
Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther (2007) 0.96
Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther (2006) 0.93
Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene (2003) 0.93
Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept (2003) 0.92
LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun (2007) 0.91
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther (2010) 0.90
Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res (2008) 0.87
Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res (2005) 0.87
Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer (2014) 0.86
RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate (2011) 0.86
Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate (2012) 0.85
Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer (2010) 0.83
Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate (2007) 0.82
Interleukin-4 activates androgen receptor through CBP/p300. Prostate (2009) 0.81
Effects of triclocarban on intact immature male rat: augmentation of androgen action. Reprod Sci (2010) 0.81
RhoGDIα downregulates androgen receptor signaling in prostate cancer cells. Prostate (2013) 0.80
STAT3 and transactivation of steroid hormone receptors. Vitam Horm (2005) 0.78
The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate (2011) 0.78
Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog (2011) 0.77
Transcriptional regulation of human RANK ligand gene expression by E2F1. Biochem Biophys Res Commun (2008) 0.76
Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol (2003) 0.75
[Primary experimental results of methylseleninic acid on the proliferation inhibition and apoptotic induction in human high-metastatic large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi (2006) 0.75
Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med (2016) 0.75
[Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways in Non-small Cell Lung Cancer Therapy.]. Zhongguo Fei Ai Za Zhi (2009) 0.75